Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ADTX | US
-0.01
-2.35%
Healthcare
Biotechnology
30/06/2024
24/04/2026
0.28
0.29
0.29
0.27
Aditxt Inc. a biotech company develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand manage and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation including skin grafting autoimmune diseases and allergies. Aditxt Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics Inc. and changed its name to Aditxt Inc. in July 2021. Aditxt Inc. was incorporated in 2017 and is headquartered in Richmond Virginia.
View LessValue Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
111.5%1 month
152.7%3 months
1297.9%6 months
943.6%-
0.37
0.69
1.22
0.28
0.02
37.49
-
-33.09M
1.19M
1.19M
-
-13.50K
-
-80.00
-3.49K
0.09
4.27
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.26
Range1M
0.87
Range3M
4.10
Rel. volume
0.26
Price X volume
178.11K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ERNA | ERNA | Biotechnology | 0.1917 | 1.04M | 0.37% | n/a | -577.12% |
| Phio Pharmaceuticals Corp | PHIO | Biotechnology | 1.19 | 1.02M | -3.25% | n/a | 0.00% |
| Galmed Pharmaceuticals Ltd | GLMD | Biotechnology | 0.6269 | 944.73K | 1.93% | n/a | 0.00% |
| Evofem Biosciences Inc | EVFM | Biotechnology | 0.0087 | 872.86K | 3.57% | 0.00 | 0.00% |
| Kala Pharmaceuticals Inc | KALA | Biotechnology | 0.1361 | 745.92K | -11.62% | n/a | 268.29% |
| Pasithea Therapeutics Corp. Common Stock | KTTA | Biotechnology | 0.69 | 720.99K | 0.10% | n/a | 0.00% |
| Virax Biolabs Group Limited Ordinary Shares | VRAX | Biotechnology | 0.1596 | 692.98K | 0.44% | n/a | 4.18% |
| Arsanis Inc | ASNS | Biotechnology | 0.0948 | 570.51K | -3.27% | n/a | 252.35% |
| Sorrento Therapeutics Inc | SRNE | Biotechnology | 0.0009 | 569.66K | -18.18% | n/a | -101.21% |
| Iterum Therapeutics plc | ITRM | Biotechnology | 0.0191 | 433.68K | 56.56% | n/a | -198.11% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.02 | 0.53 | Cheaper |
| Ent. to Revenue | 37.49 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.69 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 1,297.93 | 72.80 | Riskier |
| Debt to Equity | 1.22 | -1.23 | Expensive |
| Debt to Assets | 0.28 | 0.25 | Par |
| Market Cap | 1.19M | 3.66B | Emerging |